5/9/2016

EspacenetClaims

Espacenet
Claims:NZ627177(A)20160226
Useoftnfinhibitorfortreatmentoferosivepolyarthritis
ClaimsnotavailableforNZ627177(A)
Claimsofcorrespondingdocument:WO2006125229(A2)

Ahighqualitytextasfacsimileinyourdesiredlanguagemaybeavailable
amongstthefollowingfamilymembers:
AU2006246721(B2)BRPI0610058(A2)CA2608728(A1)CN101500607(A)
EP2500037(A2)JP2008545662(A)KR20130086254(A)TW201100446(A)
US2007071747(A1)WO2006125229(A2)CA2898009(A1)CA2903138(A1)
CN102961746(A)JP2012211138(A)JP2015157821(A)KR101465456(B1)TWI399383(B)
US2014286867(A1)more

Originalclaims
Claimstree

TheEPOdoesnotacceptanyresponsibilityfortheaccuracyofdataandinformation
originatingfromotherauthoritiesthantheEPOinparticular,theEPOdoesnot
guaranteethattheyarecomplete,uptodateorfitforspecificpurposes.
Whatisclaimed:
1.Amethodfortreatingahumansubjectsufferingfromerosivepolyarthritis,
comprisingadministeringtothesubjectaTNF[alpha]antibody,orantigenbinding
portionthereof,suchthaterosivepolyarthritisistreated.
16.AmethodfortestingtheefficacyofaTNF[alpha]antibody,orantigenbinding
portionthereof,fordecreasingradiographicprogressionofjointdiseaseassociated
witherosivepolyarthritiscomprisingdeterminingtheefficacyoftheTNFaantibody,or
antigenbindingportionthereof,usingamodifiedTotalSharpScore(mTSS)ofa
patientpopulationhavingjointdiseaseassociatedwitherosivepolyarthritisanda
mTSSofthepatientpopulationfollowingadministrationoftheTNF[alpha]antibody,
orantigenbindingportionthereof,whereinnochangeoradecreaseinthemTSS
indicatesthattheTNF[alpha]antibody,orantigenbindingportionthereof,is
efficaciousfordecreasingradiographicprogressionofjointdiseaseassociatedwith
erosivepolyarthritis.
31.AmethodformonitoringtheeffectivenessofaTNF[alpha]antibody,orantigen
bindingportionthereof,forthetreatmentoferosivepolyarthritisinahumansubject
comprisingdeterminingtheeffectivenessoftheTNF[alpha]antibody,orantigen
bindingportionthereof,usingabaselinemodifiedTotalSharpScore(mTSS)ofa
patientpopulationhavingerosivepolyarthritisandamTSSscoreofapatient
populationfollowingadministrationoftheTNF[alpha]antibody,orantigenbinding
portionthereof,whereinaresultselectedfromthegroupconsistingofi)adecrease
inthemTSSinabout927%ofthepatientpopulationii)nochangeinthemTSSin
about6573%ofthepatientpopulationandiii)anincreaseinthemTSSinabout9
28%ofthepatientpopulationindicatesthattheTNF[alpha]antibody,orantigen
bindingportionthereof,iseffectiveattreatingerosivepolyarthritis.
https://worldwide.espacenet.com/publicationDetails/claims?DB=EPODOC&ND=4&locale=en_EP&FT=D&date=20160226&CC=NZ&NR=627177A&KC=A&tr

1/2

5/9/2016

EspacenetClaims

37.AmethodfortestingtheefficacyofaTNF[alpha]antibody,orantigenbinding
portionthereof,totreaterosivepolyarthritisassociatedwithpsoriaticarthritis
comprisingdeterminingtheefficacyoftheTNF[alpha]antibody,orantigenbinding
portionthereof,usingabaselinemodifiedTotalSharpScore(mTSS)andeithera
baselinePsoriasisAreaandSeverityIndex(PASI)scoreorabaselineACRscoreof
apatientpopulationhavingerosivepolyarthritisincomparisonwiththemTSSand
eitherthePASIortheACRscoreofthepatientpopulationfollowingadministrationof
theNFaantibody,orantigenbindingportionthereof,whereinnochangeora
decreaseinthemTSSandeitheranACR20responseachievedinatleastabout
57%oraPASI50responseachievedinatleastabout75%ofthepatientpopulation,
indicatesthattheTNF[alpha]antibody,orantigenbindingportionthereof,is
efficaciousforthetreatmentoferosivepolyarthritisassociatedwithpsoriaticarthritis.
43.Amethodfortreatingerosivepolyarthritiscomprisingadministeringtoasubject
havingerosivepolyarthritis,adalimumabonabiweeklydosingregimen.
45.AkitcomprisingapharmaceuticalcompositioncomprisingaTNF[alpha]antibody,
oranantigenbindingportionthereof,andapharmaceuticallyacceptablecarrier,and
instructionsforadministrationofthepharmaceuticalcompositionforthetreatmentof
erosivepolyarthritis.
50.Anarticleofmanufacturecomprisinga)apackagingmaterialb)aTNF[alpha]
antibody,orantigenbindingportionthereofandc)alabelorpackageinsert
containedwithinthepackagingmaterialindicatingthattheTNF[alpha]antibody,or
antigenbindingportionthereof,canbeusedforthetreatmentoferosivepolyarthritis.
51.Anarticleofmanufacturecomprisinga)apackagingmaterialb)aTNF[alpha]
antibody,orantigenbindingportionthereof,andc)alabelorpackageinsert
containedwithinthepackagingmaterialindicatingthattheTNF[alpha]antibody,or
antigenbindingportionthereof,canbeusedfortoinhibitradiographicprogressionof
jointdisease.
1

16

10

11

8 12 9 13

14

17

15

18

19

31

20

21

22

28

29

23

24

25

26

27
30

32

37

33

34
35

36

38

40

39

41

43
42

44

45

50

46

48

47

49

51
52

53

54
55

56

Estapginaessegura

https://worldwide.espacenet.com/publicationDetails/claims?DB=EPODOC&ND=4&locale=en_EP&FT=D&date=20160226&CC=NZ&NR=627177A&KC=A&tr

2/2